Skip to main content
. Author manuscript; available in PMC: 2010 Mar 1.
Published in final edited form as: Pharmacol Ther. 2008 Nov 27;121(3):253–264. doi: 10.1016/j.pharmthera.2008.11.003

Fig. 2.

Fig. 2

EGFR signaling through the PI3K/Akt pathway. Erlotinib and gelfitinib interfere with autophosphorylation of EGFR. In tumors that exhibit upregulation of IGFR, signaling of that receptor through Ras/Raf can bypass the block and generate sufficient activated PI3K to signal through Akt; these tumors are therefore resistant to erlotinib and gelfitinib. Adjunctive treatment with farnesyl transferase inhibitors or nelfinavir can overcome this resistance.